Omadacycline vs. Moxifloxacin for the Treatment of Community-Acquired Bacterial Pneumonia

  • participants needed
  • sponsor
    Paratek Pharmaceuticals Inc
Updated on 29 January 2023


The purpose of this study is to evaluate the safety and efficacy of omadacycline as compared to moxifloxacin in the treatment of adults with community-acquired bacterial pneumonia.

Condition Community-acquired Pneumonia, Bacterial Pneumonia
Treatment moxifloxacin, Omadacycline
Clinical Study IdentifierNCT04779242
SponsorParatek Pharmaceuticals Inc
Last Modified on29 January 2023

Similar trials to consider


Not finding what you're looking for?

Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.

Sign up as volunteer

user name

Added by • 



Reply by • Private

Lorem ipsum dolor sit amet consectetur, adipisicing elit. Ipsa vel nobis alias. Quae eveniet velit voluptate quo doloribus maxime et dicta in sequi, corporis quod. Ea, dolor eius? Dolore, vel!

  The passcode will expire in None.

No annotations made yet

Add a private note
  • abc Select a piece of text from the left.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.
Add a private note